Charles River Laboratories International, Inc. (CRL)

FairStock Score: 38/100 — MIXED

Key Financials

Strengths

• Generates substantial free cash flow of $572.4M despite current losses, indicating underlying operational cash generation
• Operates in essential pharmaceutical and biotech services with predictable recurring revenue
• Large installed customer base across drug discovery and safety testing creates switching costs
• Established market position with 18,300 employees and global infrastructure

Concerns

• Latest quarter shows catastrophic -27.82% net margin with $276.6M loss on $1B revenue—profitability trajectory unclear
• Negative ROE of -4.23% and ROCE of 4.24% indicate management is destroying shareholder capital
• Piotroski F-Score of 3/9 signals rapid deterioration in financial metrics and quality
• Altman Z-Score of 1.82 places company in financial distress zone with elevated bankruptcy risk

AI Analysis

Charles River presents a classic value trap masquerading as opportunity. On the surface, we have a business with essential services—drug discovery and safety testing—operating in a sector with structural tailwinds. The company generates $572.4M in free cash flow, suggesting operational capability. However, Graham would immediately raise red flags. The latest quarter shows a $276.6M net loss on $994.2M revenue—a devastating -27.82% margin that cannot be dismissed as temporary. A Piotroski F-Score of merely 3/9 indicates deteriorating financial quality, while the Altman Z-Score of 1.82 places the company in the distress zone. The ROE of -4.23% means management is destroying shareholder value, not creating it. Most troubling: I cannot calculate a meaningful P/E ratio because there are no earnings. The company is burning through value despite substantial revenue. The debt-to-equity ratio of 0.82 is manageable, but leverage amplifies downside risk during distress. At $174.46, trading from a 52-week low of $91.86, the stock reflects a market that has lost confidence. The FairStock Score of 40/100 confirms this is uninvestable at present prices. I've learned to be suspicious of companies requiring me to 'wait for the turnaround.' CRL's high beta of 1.65 suggests it's a volatile, high-risk security. Without clarity on when profitability returns and what drove this collapse, I must pass. Graham's margin of safety is entirely absent here.

Bull Case

If the Q4 loss represents a one-time charge or accounting adjustment rather than operational collapse, the company's essential service positioning and strong FCF generation could support a recovery at lower prices. Management execution on cost restructuring could return the business to 15-20% net margins within 12-18 months, justifying a re-rating.

Bear Case

The negative profitability trend may reflect structural headwinds in drug development spending or increased competitive pressure that persists. Continued cash burn could force dilutive equity issuance or covenant violations on debt, leading to further value destruction for shareholders.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer